| 产品名称： | 807.31 |
|---|---|
| 商品货号： | TS212787 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications： | The hybridoma cell line 807.31 secretes a mouse monoclo-nal antibody (IgG1) reactive with the G1 envelope glycoprotein of La Crosse Virus. This antibody as well as 807.15 (ATCC CRL-2287) and 807.33 (ATCC CRL-2290) is useful for identifying infection by La Crosse virus and other California serogroup Bunyaviruses. The 807.31 antibody has been used in ELISA, Western Blot, immunoprecipitation, immunofluorescence and neutralization assays. The line was produced by fusing P3X63Ag8.653 myeloma cells with spleen cells from BALB/c mice that had been immunized with La Crosse Virus. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | The line was produced by fusing P3X63Ag8.653 myeloma cells with spleen cells from BALB/c mice that had been immunized with La Crosse Virus. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against the G1 envelope glycoprotein of La Crosse Virus |
| Cellular Products： | immunoglobulin; monoclonal antibody; against the G1 envelope glycoprotein of La Crosse Virus |
| Comments： | The hybridoma cell line 807.31 secretes a mouse monoclo-nal antibody (IgG1) reactive with the G1 envelope glycoprotein of La Crosse Virus. This antibody as well as 807.15 (ATCC CRL-2287) and 807.33 (ATCC CRL-2290) is useful for identifying infection by La Crosse virus and other California serogroup Bunyaviruses. The 807.31 antibody has been used in ELISA, Western Blot, immunoprecipitation, immunofluorescence and neutralization assays. The antibody does not react with the G2 or L proteins of La Crosse virus. The line was produced by fusing P3X63Ag8.653 myeloma cells with spleen cells from BALB/c mice that had been immunized with La Crosse Virus. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by addition of fresh Medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 x 105 viable cells/mL.xa0 Maintain cultures at a cell concentration between 1 x 105 and 1 x 106 cells/mL. Do not allow the cell concentration to exceed 1 x 106 cells/mL. Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | Complete growth medium described above supplemented with 5% (v/v) DMSO.xa0 Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Culture Conditions： | Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5% |
| Isotype： | IgG1 |
| Name of Depositor： | F Gonzalez-Scarano |
| References： | Gonzalez-Scarano F, et al. Characterization of monoclonal antibodies against the G1 and N proteins of LaCrosse and Tahyna, two California serogroup bunyaviruses. Virology 120: 42-53, 1982. PubMed: 7101727 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online. |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | 807.31 |
|---|---|
| 商品货号： | TS212787 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications： | The hybridoma cell line 807.31 secretes a mouse monoclo-nal antibody (IgG1) reactive with the G1 envelope glycoprotein of La Crosse Virus. This antibody as well as 807.15 (ATCC CRL-2287) and 807.33 (ATCC CRL-2290) is useful for identifying infection by La Crosse virus and other California serogroup Bunyaviruses. The 807.31 antibody has been used in ELISA, Western Blot, immunoprecipitation, immunofluorescence and neutralization assays. The line was produced by fusing P3X63Ag8.653 myeloma cells with spleen cells from BALB/c mice that had been immunized with La Crosse Virus. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | The line was produced by fusing P3X63Ag8.653 myeloma cells with spleen cells from BALB/c mice that had been immunized with La Crosse Virus. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against the G1 envelope glycoprotein of La Crosse Virus |
| Cellular Products： | immunoglobulin; monoclonal antibody; against the G1 envelope glycoprotein of La Crosse Virus |
| Comments： | The hybridoma cell line 807.31 secretes a mouse monoclo-nal antibody (IgG1) reactive with the G1 envelope glycoprotein of La Crosse Virus. This antibody as well as 807.15 (ATCC CRL-2287) and 807.33 (ATCC CRL-2290) is useful for identifying infection by La Crosse virus and other California serogroup Bunyaviruses. The 807.31 antibody has been used in ELISA, Western Blot, immunoprecipitation, immunofluorescence and neutralization assays. The antibody does not react with the G2 or L proteins of La Crosse virus. The line was produced by fusing P3X63Ag8.653 myeloma cells with spleen cells from BALB/c mice that had been immunized with La Crosse Virus. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by addition of fresh Medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 x 105 viable cells/mL.xa0 Maintain cultures at a cell concentration between 1 x 105 and 1 x 106 cells/mL. Do not allow the cell concentration to exceed 1 x 106 cells/mL. Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | Complete growth medium described above supplemented with 5% (v/v) DMSO.xa0 Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Culture Conditions： | Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5% |
| Isotype： | IgG1 |
| Name of Depositor： | F Gonzalez-Scarano |
| References： | Gonzalez-Scarano F, et al. Characterization of monoclonal antibodies against the G1 and N proteins of LaCrosse and Tahyna, two California serogroup bunyaviruses. Virology 120: 42-53, 1982. PubMed: 7101727 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online. |
